Amalgamated Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Amalgamated Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$18.1M	Buy	+69,389	New	+$16.5M	0.14%	111

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Amalgamated Financial's VRTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2022: 69,389 shares worth $18.1M. The stake represents 0.14% of the portfolio and ranks #111 among its holdings.

1,072 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Amalgamated Financial held 69,389 shares of Vertex Pharmaceuticals worth $18.1M as of Q1 2022.
Vertex Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Vertex Pharmaceuticals made up 0.14% of Amalgamated Financial's portfolio in Q1 2022, its #111 holding.
1,072 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.